Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 12
2017 26
2018 25
2019 20
2020 16
2021 15
2022 16
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Huntington's disease: a clinical review.
McColgan P, Tabrizi SJ. McColgan P, et al. Eur J Neurol. 2018 Jan;25(1):24-34. doi: 10.1111/ene.13413. Epub 2017 Sep 22. Eur J Neurol. 2018. PMID: 28817209 Review.
Clinical Features of Huntington's Disease.
Ghosh R, Tabrizi SJ. Ghosh R, et al. Adv Exp Med Biol. 2018;1049:1-28. doi: 10.1007/978-3-319-71779-1_1. Adv Exp Med Biol. 2018. PMID: 29427096 Review.
A biological classification of Huntington's disease: the Integrated Staging System.
Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, Mestre TA, Panagoulias J, Ross CA, Zauderer M, Mullin AP, Romero K, Sivakumaran S, Turner EC, Long JD, Sampaio C; Huntington's Disease Regulatory Science Consortium (HD-RSC). Tabrizi SJ, et al. Lancet Neurol. 2022 Jul;21(7):632-644. doi: 10.1016/S1474-4422(22)00120-X. Lancet Neurol. 2022. PMID: 35716693 Review.
Targeting Huntingtin Expression in Patients with Huntington's Disease.
Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM; Phase 1–2a IONIS-HTTRx Study Site Teams. Tabrizi SJ, et al. N Engl J Med. 2019 Jun 13;380(24):2307-2316. doi: 10.1056/NEJMoa1900907. Epub 2019 May 6. N Engl J Med. 2019. PMID: 31059641 Clinical Trial.
Polyglutamine diseases.
Bunting EL, Hamilton J, Tabrizi SJ. Bunting EL, et al. Curr Opin Neurobiol. 2022 Feb;72:39-47. doi: 10.1016/j.conb.2021.07.001. Epub 2021 Sep 3. Curr Opin Neurobiol. 2022. PMID: 34488036 Review.
Huntington disease.
Ghosh R, Tabrizi SJ. Ghosh R, et al. Handb Clin Neurol. 2018;147:255-278. doi: 10.1016/B978-0-444-63233-3.00017-8. Handb Clin Neurol. 2018. PMID: 29325616 Review.
The Prevalence of Huntington's Disease.
Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJ, Smeeth L. Rawlins MD, et al. Neuroepidemiology. 2016;46(2):144-53. doi: 10.1159/000443738. Epub 2016 Jan 30. Neuroepidemiology. 2016. PMID: 26824438 Free article. Review.
An MDS Evidence-Based Review on Treatments for Huntington's Disease.
Ferreira JJ, Rodrigues FB, Duarte GS, Mestre TA, Bachoud-Levi AC, Bentivoglio AR, Burgunder JM, Cardoso F, Claassen DO, Landwehrmeyer GB, Kulisevsky J, Nirenberg MJ, Rosser A, Roth J, Seppi K, Slawek J, Furr-Stimming E, Tabrizi SJ, Walker FO, Vandenberghe W, Costa J, Sampaio C. Ferreira JJ, et al. Mov Disord. 2022 Jan;37(1):25-35. doi: 10.1002/mds.28855. Epub 2021 Nov 29. Mov Disord. 2022. PMID: 34842303 Review.
119 results